It’s not often you get excited talking about company mergers, but a deal announced today is something worth getting excited about, particularly if you have type 1 diabetes (T1D).   Today Vertex announced it was buying ViaCyte for $320 million in cash. Why is that important? Because both companies are working on developing stem cell therapies … Continue reading A big deal for type 1 diabetes